Linical Co., Ltd. (2183.T)
JPY 330.0
(0.92%)
JPY 330.0
(0.92%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | - JPY | -100.0% |
| 2022 | 1.29 Billion JPY | 5.99% |
| 2021 | 1.22 Billion JPY | -11.18% |
| 2020 | 1.37 Billion JPY | 38.32% |
| 2019 | 993.46 Million JPY | 16.56% |
| 2018 | 852.32 Million JPY | 93.59% |
| 2017 | 440.27 Million JPY | -8.48% |
| 2016 | 481.07 Million JPY | 5.29% |
| 2015 | 456.89 Million JPY | 128.78% |
| 2014 | 199.7 Million JPY | 30112.71% |
| 2013 | 661 Thousand JPY | -99.46% |
| 2012 | 122.92 Million JPY | 0.0% |
| 2011 | - JPY | 0.0% |
| 2010 | - JPY | -100.0% |
| 2009 | 623 Thousand JPY | 0.0% |
| 2008 | - JPY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 230 Million JPY | 0.0% |
| 2023 Q2 | 1.37 Billion JPY | -15.28% |
| 2023 FY | - JPY | -100.0% |
| 2023 Q4 | - JPY | 0.0% |
| 2023 Q3 | - JPY | -100.0% |
| 2023 Q1 | 1.62 Billion JPY | 25.5% |
| 2022 Q1 | 1.36 Billion JPY | 11.91% |
| 2022 Q2 | 1.73 Billion JPY | 27.1% |
| 2022 Q3 | 1.4 Billion JPY | -19.15% |
| 2022 Q4 | 1.29 Billion JPY | -7.83% |
| 2022 FY | 1.29 Billion JPY | 5.99% |
| 2021 Q2 | 1.13 Billion JPY | -18.56% |
| 2021 Q1 | 1.39 Billion JPY | 1.64% |
| 2021 Q3 | 1.18 Billion JPY | 3.96% |
| 2021 Q4 | 1.22 Billion JPY | 3.22% |
| 2021 FY | 1.22 Billion JPY | -11.18% |
| 2020 FY | 1.37 Billion JPY | 38.32% |
| 2020 Q2 | 991.3 Million JPY | 10.13% |
| 2020 Q1 | 900.13 Million JPY | -9.36% |
| 2020 Q3 | 1.2 Billion JPY | 21.51% |
| 2020 Q4 | 1.37 Billion JPY | 14.08% |
| 2019 FY | 993.46 Million JPY | 16.56% |
| 2019 Q4 | 993.06 Million JPY | -4.57% |
| 2019 Q1 | 1.11 Billion JPY | 30.47% |
| 2019 Q3 | 1.04 Billion JPY | 11.15% |
| 2019 Q2 | 936.16 Million JPY | -15.83% |
| 2018 Q1 | 534.84 Million JPY | 21.31% |
| 2018 FY | 852.32 Million JPY | 93.59% |
| 2018 Q4 | 852.43 Million JPY | 19.57% |
| 2018 Q3 | 712.92 Million JPY | 17.75% |
| 2018 Q2 | 605.47 Million JPY | 13.2% |
| 2017 Q4 | 440.9 Million JPY | -13.89% |
| 2017 Q1 | 487.08 Million JPY | 1.17% |
| 2017 FY | 440.27 Million JPY | -8.48% |
| 2017 Q2 | 571.9 Million JPY | 17.41% |
| 2017 Q3 | 512.04 Million JPY | -10.47% |
| 2016 Q4 | 481.46 Million JPY | 3.71% |
| 2016 Q1 | 385.04 Million JPY | -15.78% |
| 2016 FY | 481.07 Million JPY | 5.29% |
| 2016 Q2 | 460.05 Million JPY | 19.48% |
| 2016 Q3 | 464.23 Million JPY | 0.91% |
| 2015 Q2 | 244.86 Million JPY | 10.01% |
| 2015 Q4 | 457.17 Million JPY | 58.35% |
| 2015 Q1 | 222.57 Million JPY | 11.45% |
| 2015 FY | 456.89 Million JPY | 128.78% |
| 2015 Q3 | 288.7 Million JPY | 17.91% |
| 2014 FY | 199.7 Million JPY | 30112.71% |
| 2014 Q1 | 168.39 Million JPY | 25376.4% |
| 2014 Q4 | 199.7 Million JPY | 33.23% |
| 2014 Q3 | 149.89 Million JPY | 234107.81% |
| 2014 Q2 | 64 Thousand JPY | -99.96% |
| 2013 Q3 | 148.13 Million JPY | 2.29% |
| 2013 Q4 | 661 Thousand JPY | -99.55% |
| 2013 FY | 661 Thousand JPY | -99.46% |
| 2013 Q1 | 116.08 Million JPY | -5.56% |
| 2013 Q2 | 144.81 Million JPY | 24.75% |
| 2012 Q1 | - JPY | 0.0% |
| 2012 Q2 | 132.29 Million JPY | 0.0% |
| 2012 Q3 | 102.55 Million JPY | -22.48% |
| 2012 Q4 | 122.92 Million JPY | 19.86% |
| 2012 FY | 122.92 Million JPY | 0.0% |
| 2011 Q1 | - JPY | 0.0% |
| 2011 FY | - JPY | 0.0% |
| 2011 Q2 | - JPY | 0.0% |
| 2011 Q3 | - JPY | 0.0% |
| 2011 Q4 | - JPY | 0.0% |
| 2010 Q3 | - JPY | 0.0% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 FY | - JPY | -100.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2009 Q1 | - JPY | 0.0% |
| 2009 FY | 623 Thousand JPY | 0.0% |
| 2009 Q4 | 623 Thousand JPY | 0.0% |
| 2009 Q3 | - JPY | 0.0% |
| 2009 Q2 | - JPY | 0.0% |
| 2008 Q4 | - JPY | 0.0% |
| 2008 FY | - JPY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 683.01 Million JPY | 100.0% |
| PRISM BioLab Co.,LTD | 17.92 Million JPY | 100.0% |
| GNI Group Ltd. | 2.33 Billion JPY | 100.0% |
| Trans Genic Inc. | 2.22 Billion JPY | 100.0% |
| MEDINET Co., Ltd. | 67.48 Million JPY | 100.0% |
| Soiken Holdings Inc. | 1.12 Billion JPY | 100.0% |
| Cytori Cell Research Institute, Inc. | 103.53 Million JPY | 100.0% |
| AnGes, Inc. | 1.61 Billion JPY | 100.0% |
| OncoTherapy Science, Inc. | 73.99 Million JPY | 100.0% |
| Nxera Pharma Co., Ltd. | 2.9 Billion JPY | 100.0% |
| Immuno-Biological Laboratories Co., Ltd. | 321.91 Million JPY | 100.0% |
| NanoCarrier Co., Ltd. | 184 Thousand JPY | 100.0% |
| Carna Biosciences, Inc. | 140.14 Million JPY | 100.0% |
| CanBas Co., Ltd. | 728 Thousand JPY | 100.0% |
| D. Western Therapeutics Institute, Inc. | 87.86 Million JPY | 100.0% |
| RaQualia Pharma Inc. | 147.93 Million JPY | 100.0% |
| Chiome Bioscience Inc. | 64.1 Million JPY | 100.0% |
| Kidswell Bio Corporation | 875.65 Million JPY | 100.0% |
| PeptiDream Inc. | 2.4 Billion JPY | 100.0% |
| Oncolys BioPharma Inc. | 5.34 Million JPY | 100.0% |
| Ribomic Inc. | 2.27 Million JPY | 100.0% |
| SanBio Company Limited | - JPY | NaN% |
| Healios K.K. | - JPY | NaN% |
| BrightPath Biotherapeutics Co., Ltd. | 1.00 JPY | 100.0% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 36 Million JPY | 100.0% |
| Delta-Fly Pharma, Inc. | - JPY | NaN% |
| StemRIM | 29 Million JPY | 100.0% |
| CellSource Co., Ltd. | 305.92 Million JPY | 100.0% |
| FunPep Company Limited | 25.54 Million JPY | 100.0% |
| Kringle Pharma, Inc. | 364.05 Million JPY | 100.0% |
| Stella Pharma Corporation | 1.11 Billion JPY | 100.0% |
| TMS Co., Ltd. | 50.02 Million JPY | 100.0% |
| Noile-Immune Biotech Inc. | 20.9 Million JPY | 100.0% |
| Cuorips Inc. | 1.04 Million JPY | 100.0% |
| K Pharma,Inc. | 10.79 Million JPY | 100.0% |
| Takara Bio Inc. | 11.85 Billion JPY | 100.0% |
| ReproCELL Incorporated | 248.14 Million JPY | 100.0% |
| PhoenixBio Co., Ltd. | 450.58 Million JPY | 100.0% |
| StemCell Institute Inc. | 42.26 Million JPY | 100.0% |
| Japan Tissue Engineering Co., Ltd. | 228.56 Million JPY | 100.0% |
| CellSeed Inc. | 46.19 Million JPY | 100.0% |